Regulated transcription of targeted genes and other biological events

• US 6,165,787 A
• Filed: 05/29/1998
• Issued: 12/26/2000
• Est. Priority Date: 02/12/1993
• Status: Expired due to Term

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation), Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Spencer, David M., Crabtree, Gerald R., Schreiber, Stuart L., Belshaw, Peter, Wandless, Thomas J.
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): SCHWARTZMAN, ROBERT A
• Application Number:
  US09/087,647
• Time in Patent Office: 942 Days
• Field of Search: 435/325, 435/350, 435/351, 435/354, 435/355, 435/366, 435/372.3, 424/93.21
• US Class Current: 435/372.3
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6425 the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07D 498/18 Bridged systems
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07H 19/01 sharing oxygen
• CPC Class Codes: C07K 14/395 from Saccharomyces
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment
• CPC Class Codes: C07K 2319/035 containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
• CPC Class Codes: C07K 2319/09 containing a nuclear localisation signal
• CPC Class Codes: C07K 2319/20 containing a tag with affinity for a non-protein ligand
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"
• CPC Class Codes: C07K 2319/42 containing a HA(hemagglutinin)-tag
• CPC Class Codes: C07K 2319/43 : containing a FLAG-tag
• CPC Class Codes: C07K 2319/60 : containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
• CPC Class Codes: C07K 2319/71 : containing domain for transcriptional activaation, e.g. VP16
• CPC Class Codes: C07K 2319/715 : containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
• CPC Class Codes: C07K 2319/81 : containing a Zn-finger domain for DNA binding
• CPC Class Codes: C07K 2319/90 : containing a motif for post-translational modification
• CPC Class Codes: C07K 7/645 : Cyclosporins; Related peptides
• CPC Class Codes: C12N 15/62 : DNA sequences coding for fusion proteins
• CPC Class Codes: C12N 15/63 : Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• CPC Class Codes: C12P 15/00 : Preparation of compounds containing at least three condensed carbocyclic rings gibbanes C12P27/00; naphthacenes C12P29/00
• CPC Class Codes: C12P 17/188 : Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms ergot-alcaloids C12P17/183

Abstract

Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

Claims

1. A eukaryotic cell comprising at least one genetic construct encoding a chimeric protein, which chimeric protein comprises:

(a) at least one ligand-binding domain which binds to a selected ligand to form a ligand cross-linked protein complex including the chimeric protein, the ligand having one or more of the following characteristics;

(i) the ligand is not a protein,

(ii) the ligand has a molecular weight less than 5 kD, and

(iii) the ligand is membrane permeable; and

(b) an action domain, which is heterologous with respect to at least one of the ligand-binding domains, and which induces a biological process in the cell as a result of formation of the ligand cross-linked protein complex.

2. The cell according to claim 1, wherein the action domain includes a cytoplasmic domain of a cell surface receptor, or a variant thereof sufficient to induce the biological process in the cell as a result of formation of the ligand cross-linked protein complex.

3. The cell according to claim 1, wherein the action domain includes a cytoplasmic domain, or a portion thereof which initiates a biological process, of a receptor selected from the group consisting of CD3ζ

, CD3η

, an IL-2 receptor, an IL-3 receptor, an IL-4 receptor, an IL-7 receptor, an IL-11 receptor, an IL-13 receptor, a GM-CSF receptor, a LIF receptor, a CNTF receptor, an oncostatin M receptor, a TGF-β

receptor, an EGF receptor, ATR2/neu, a HER2/neu, a HER3/c-erbB-3, Xmrk, an insulin receptor, an IGF-1 receptor, IRR, PDGF receptor, a CSF-1 receptor, c-kit, STK-1/flk-2, an FGF receptor, flg, bek, an NGF receptor, Ror1 and Ror2.

4. The cell according to claim 1, wherein the biological process is selected from the group consisting of channel opening, ion release, acylation, methylation, hydrolysis, phosphorylation, dephosphorylation, change in redox states, and rearrangement reactions.

5. The cell according to claim 1, wherein the action domain has an enzymatic activity selected from the group consisting of a phosphatase activity, a reductase activity, a cyclooxygenase activity and a protease activity.

6. The cell according to claim 1 wherein the action domain has a kinase activity.

7. The cell according to claim 1, wherein the biological process includes cell death.

8. The cell according to claim 1, wherein the action domain comprises a cytoplasmic portion of a Fas or TNF receptor sufficient to induce the biological process as a result of formation of the ligand cross-linked protein complex.

9. The cell according to claim 1, wherein the biological process includes regulation of gene transcription.

10. The cell according to claim 1, wherein the chimeric protein further comprises an intracellular targeting domain which comprises a secretory leader sequence, a lipid membrane retention domain, a nuclear localization domain or a vesicle targeting domain.

11. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of a steroid receptor.

12. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises an antibiotic binding domain.

13. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises an antibody domain.

14. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of a cyclophilin receptor.

15. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises a ligand binding domain of an immunophilin.

16. The cell according to claim 1, wherein at least one of the ligand-binding domains binds to FK506, FK520 rapamycin or a derivative of any of the foregoing.

17. The cell according to claim 1, wherein at least one of the ligand-binding domains is a ligand binding domain of a human FK506 Binding Protein.

18. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises an FK506 binding domain of a human FK506 Binding Protein FKBP12, or a variant thereof in which one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 are replaced by other amino acid residues.

19. The cell according to claim 1, wherein the chimeric protein includes two or more ligand-binding domains.

20. The cell according to claim 1, wherein the chimeric protein includes two or more ligand-binding domains having different ligand binding specific specificities.

21. The cell according to claim 1, wherein at least one of the ligand-binding domains is from 50 to 350 amino acid residues in length.

22. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises a naturally-occurring peptide sequence.

23. The cell according to claim 1, wherein at least one of the ligand-binding domains comprises a non-naturally-occurring peptide sequence.

24. The cell according to claim 1, wherein the genetic construct comprises one or more of(i) an origin of replication, (ii) a selectable marker, (iii) an amplifiable marker, and (iv) a transcriptional regulatory sequence for expressing the chimeric protein in mammalian cells.

25. The cell according to claim 9, wherein the action domain includes a DNA binding domain, transcriptional activation domain, or a transcriptional repressor domain.

26. The cell according to claim 9, wherein the biological process includes regulation of a gene having a transcriptional regulatory element selected from the group consisting of a cAMP responsive element, an SRE, a VL30, an RSRF, an ISRE, a GAS, an ARRE-1 and an ARRE-2.

27. The cell according to claim 9, wherein the biological process includes regulation of expression of an endogenous gene of the cell.

28. The cell according to claim 9, wherein the biological process includes regulation of expression of a heterologous gene included in the cell.

29. The cell according to claim 10, wherein the intracellular targeting domain is a membrane retention domain including a plasma membrane targeting sequence for attachment of a myristoyl moiety or prenyl moiety.

30. The cell according to claim 10, wherein the intracellular targeting domain is a membrane retention domain including a transmembrane retention domain.

31. The cell according to claim 10, wherein the intracellular targeting domain is a nuclear localization domain including a bipartite basic repeat for directing the chimeric protein to the nucleus.

32. The cell according to claim 12, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of a tetracycline receptor.

33. The cell according to claim 16, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of an FK506 Binding Protein.

34. The cell according to claim 18, wherein one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 of the FKBP12 are replaced by amino acids independently selected from the group consisting of Val, Ala, Gly and Met.

35. The cell according to claim 18, wherein one or both of Phe36 and Asp37 are replaced by amino acids independently selected from the group consisting of Val and Ala.

36. The cell according to claim 18, wherein Phe36 is replaced by a valine residue.

37. The cell according to claim 18, wherein Phe36 is replaced by a methionine residue.

38. The cell according to claim 21, wherein at least one of the ligand-binding domains is from 50 to 200 amino acid residues in length.

39. The cell according to claim 23, wherein the non-naturally-occurring ligand-binding domain differs from a naturally-occurring ligand binding domain by one or more amino acid residues, and binds a ligand which is not bound by the naturally-occurring ligand binding domain.

40. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-6 M.

41. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein the eukaryotic cell is a mammalian cell.

42. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains is provided in the chimeric fused protein as an intracellular domain.

43. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of an intracellular protein.

44. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains binds to a ligand which is a synthetic organic molecule having a molecular weight of less than 5 kD.

45. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains binds to a ligand which is membrane permeable.

46. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein at least one of the ligand-binding domains binds to a ligand which is a macrocyclic compound.

47. The cell according to any of claims 1, 2, 7, 9, 10, 18, 23, 25, 27, 28, 33, 36 or 39, wherein the ligand cross-linked protein complex comprises two or more chimeric proteins.

48. The cell according to claim 40, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-8 M.

49. The cell according to claim 41, wherein the mammalian cell is a human cell.

50. The cell according to claim 41, wherein the mammalian cell is a cell type selected from the group consisting of mesenchymal, cutaneous, mucosal, stromal, spleen, reticuloendothelial, epithelial, endothelial, kidney, gastrointestinal and pulmonary cells.

51. The cell according to claim 41, wherein the mammalian cell is a muscle cell.

52. The cell according to claim 41, wherein the mammalian cell is a stem cell or a progenitor cell.

53. The cell according to claim 41, wherein the mammalian cell is a hematopoietic cell.

54. The cell according to claim 41, wherein the mammalian cell is a neural cell.

55. The cell according to claim 41, wherein the mammalian cell is a hepatic cell.

56. The cell according to claim 41, wherein the mammalian cell is an equine cell, a bovine cell, a murine cell, an ovine cell, a canine cell or a feline cell.

57. The cell according to claim 41, wherein at least one of the ligand-binding domains is provided in the chimeric fused protein as an intracellular domains and the ligand is membrane permeable.

58. The cell according to claim 46, wherein the macrocyclic compound comprises a macrolide.

59. The cell according to claim 57, wherein at least one of the ligand-binding domains binds to a ligand which is a synthetic organic molecule having a molecular weight of less than 5 kD.

60. The cell according to claim 59, wherein the ligand cross-linked protein complex comprises two or more chimeric proteins.

61. The cell according to claim 60, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-6 M.

86. The cell according to claim 1 or 62, wherein the genetic construct is a viral vector.

104. The cell according to claim 86, wherein the viral vector is an adenoviral vector.

105. The cell according to claim 86, wherein the viral vector is an adeno-associated viral vector.

106. The cell according to claim 86, wherein the viral vector is a Herpes simplex viral vector.

107. The cell according to claim 86, wherein the viral vector is a retroviral vector.

62. A eukaryotic cell comprising two or more genetic constructs, each encoding a different chimeric protein, each of which chimeric proteins independently comprises

(a) at least one ligand-binding domain which binds to a selected ligand to form a ligand cross-linked protein complex containing at least the two different chimeric proteins, the ligand having one or more of the following characteristics:

(i) the ligand is not a protein,

(ii) the ligand has a molecular weight less than 5 kD, and

(iii) the ligand is membrane permeable; and

(b) at least one of

(i) an action domain, which is heterologous with respect to at least one of the ligand-binding domains, and which induces a biological process as a result of formation of the ligand cross-linked protein complex, and

(ii) an intracellular targeting domain, which is heterologous with respect to at least one of the ligand-binding domains, and which induces cellular localization of the ligand cross-linked protein complex,

with the proviso that at least one of the chimeric proteins includes an action domain.

63. The cell according to claim 62, wherein the biological process includes regulation of gene transcription.

64. The cell according to claim 62, wherein at least one of the chimeric proteins further comprises a nuclear localization signal.

65. The cell according to claim 62, which further comprises a heterologous target gene, the expression of which is dependent on formation of the ligand cross-linked protein complex.

66. The cell according to claim 62, wherein a first chimeric protein encoded by the genetic constructs includes an action domain and further comprises an intracellular targeting domain which comprises a secretory leader sequence, a lipid membrane retention domain, a nuclear localization domain or a vesicle targeting domain.

67. The cell according to claim 62, wherein the action domain includes a cytoplasmic domain of a cell surface receptor, or a variant thereof sufficient to induce the biological process in the cell as a result of formation of the ligand cross-linked protein complex.

68. The cell according to claim 62, wherein the action domain includes a cytoplasmic domain, or a portion thereof which initiates a biological process, of a receptor selected from the group consisting of CD3ζ

, CD3η

, an IL-2 receptor, an IL-3 receptor, an IL-4 receptor, an IL-7 receptor, an IL-11 receptor, an IL-13 receptor, a GM-CSF receptor, a LIF receptor, a CNTF receptor, an oncostatin M receptor, a TGF-β

receptor, an EGF receptor, ATR2/neu, a HER2/neu, a HER3/c-erbB-3, Xmrk, an insulin receptor, an IGF-1 receptor, IRR, PDGF receptor, a CSF-1 receptor, c-kit, STK-1/flk-2, an FGF receptor, flg, bek, an NGF receptor, Ror1 and Ror2.

69. The cell according to claim 62, wherein the action domain comprises a cytoplasmic portion of a Fas or TNF receptor sufficient to induce the biological process as a result of formation of the ligand cross-linked protein complex.

70. The cell according to claim 62, wherein the biological process is selected from the group consisting of channel opening, ion release, acylation, methylation, hydrolysis, phosphorylation, dephosphorylation, change in redox states, and rearrangement reactions.

71. The cell according to claim 62, wherein the action domain has an enzymatic activity selected from the group consisting of a phosphatase activity, a reductase activity, a cyclooxygenase activity and a protease activity.

72. The cell according to claim 62, wherein the action domain has a kinase activity.

73. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises a ligand-binding domain of a steroid receptor.

74. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises an antibiotic binding domain.

75. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises an antibody domain.

76. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises a ligand-binding domain of a cyclophilin receptor.

77. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises a ligand-binding domain of an immunophilin.

78. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins binds to FK506, FK520, rapamycin or a derivative of any of the foregoing.

79. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises a ligand-binding domain of an FK506 Binding Protein.

80. The cell according to claim 62, wherein at least one of the ligand-binding domains comprises an FK506 binding domain of human FK506 Binding Protein FKBP12, or a variant thereof in which one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 are replaced by a different amino acid.

81. The cell according to claim 62, wherein one or more of the chimeric proteins includes two or more ligand-binding domains.

82. The cell according to claim 62, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins is from 50 to 350 amino acid residues in length.

83. The cell according to claim 62, wherein at least one of the ligand-binding domains comprises a naturally-occurring ligand-binding domain.

84. The cell according to claim 62, wherein at least one of the ligand-binding domains comprises a non-naturally-occurring peptide sequence.

85. The cell according to claim 62, wherein the genetic constructs comprise one or more of (i) an origin of replication, (ii) a selectable marker, (iii) an amplifiable marker, and (iv) a transcriptional regulatory sequence for expressing the chimeric protein in mammalian cells.

87. The cell according to claim 63, wherein the biological process includes regulation of expression of an endogenous gene of the cell.

88. The cell according to claim 63, wherein the biological process includes regulation of expression of a heterologous gene included in the cell.

89. The cell according to claim 63, wherein the biological process includes regulation of a target gene having a transcriptional regulatory element selected from the group consisting of a cAMP responsive element, an SRE, a VL30, an RSRF, an ISRE, a GAS, an ARRE-1 and an ARRE-2.

90. The cell according to claim 63, wherein a first chimeric protein encoded by the genetic constructs comprises a DNA binding domain and at least one ligand-binding domain, and a second chimeric protein encoded by the genetic constructs comprises a transcription activation domain and at least one ligand-binding domain.

91. The cell according to claim 66, wherein the intracellular targeting domain is a membrane retention domain including a plasma membrane targeting sequence for attachment of a myristoyl moiety or prenyl moiety.

92. The cell according to claim 66, wherein the intracellular targeting domain is a membrane retention domain including a transmembrane retention domain.

93. The cell according to claim 66, wherein the intracellular targeting domain is a nuclear localization domain including a bipartite basic repeat for directing the chimeric protein to the nucleus.

94. The cell according to claim 62, 67 or 68, wherein a first chimeric protein encoded by the genetic constructs comprises at least one ligand binding domain and a membrane targeting domain, and a second chimeric protein encoded by the genetic constructs comprises at least one ligand binding domain and an action domain.

95. The cell according to claim 74, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins comprises a ligand-binding domain of a tetracycline receptor.

96. The cell according to claim 79, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins is a ligand binding domain of a human FK506 Binding Protein.

97. The cell according to claim 80, wherein one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 of the FKBP12 are replaced by a different amino acid independently selected from the group consisting of Val, Ala, Gly and Met.

98. The cell according to claim 80, wherein one or both of Phe36 and Asp37 are replaced by a different amino acid independently selected from the group consisting of Val and Ala.

99. The cell according to claim 80, wherein Phe36 is replaced by a valine residue.

100. The cell according to claim 80, wherein Phe36 is replaced by a methionine residue.

101. The cell according to claim 81, wherein two or more ligand-binding domains have different ligand binding specificities.

102. The cell according to claim 82, wherein at least one of the ligand-binding domains of one or more of the chimeric proteins is from 50 to 200 amino acid resides in length.

103. The cell according to claim 84, wherein the non-naturally-occurring ligand-binding domain differs from a naturally-occurring ligand binding domain by one or more amino acid residues, and binds a ligand which is not bound by the naturally-occurring ligand binding domain.

108. The cell according to claim 90, wherein the DNA binding or activation domains are derived from GAL4.

109. The cell according to claim 90, which further comprises a heterologous target gene operably linked to a transcriptional regulatory element which binds the DNA-binding domain.

110. The cell according to any of claims 62, 63, 65, 66, 79, 80, 89, 87, 88, 90, 99, 103, or 109, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-6 M.

111. The cell of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein the eukaryotic cell is a mammalian cell.

112. The cell according to any of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein at least one of the ligand-binding domains is provided in the chimeric fused protein as an intracellular domain.

113. The cell according to any of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein at least one of the ligand-binding domains comprises a ligand-binding domain of an intracellular protein.

114. The cell according to any of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein at least one of the ligand-binding domains binds a ligand which is a synthetic organic molecule having a molecular weight of less than 5 kD.

115. The cell according to any of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein at least one of the ligand-binding domains binds a ligand which is membrane permeable.

116. The cell according to any of claims 62, 63, 65, 66, 79, 80, 84, 87, 88, 90, 99, 103 or 109, wherein at least one of the ligand-binding domains binds a ligand which is a macrocyclic compound.

117. The cell according to claim 110, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-8 M.

118. The cell according to claim 111, wherein the mammalian cell is a human cell.

119. The cell according to claim 111, wherein the mammalian cell is a cell type selected from the group consisting of mesenchymal, cutaneous, mucosal, stromal, spleen, reticuloendothelial, epithelial, endothelial, kidney, gastrointestinal and pulmonary cells.

120. The cell according to claim 111, wherein the mammalian cell is a muscle cell.

121. The cell according to claim 111, wherein the mammalian cell is a stem cell or a progenitor cell.

122. The cell according to claim 111, wherein the mammalian cell is a hematopoietic cell.

123. The cell according to claim 111, wherein the mammalian cell is a neural cell.

124. The cell according to claim 111, wherein the mammalian cell is a hepatic cell.

125. The cell according to claim 111, wherein the mammalian cell is equine cell, a bovine cell, a murine cell, an ovine cell, a canine cell or a feline cell.

126. The cell according to claim 111, wherein at least one of the ligand-binding domains is provided in the chimeric fused protein as an intracellular domain and binds a ligand which is membrane permeable.

127. The cell according to claim 116, wherein the macrocyclic compound comprises a macrolide.

128. The cell according to claim 126, wherein at least one of the ligand-binding domains binds a ligand which is a synthetic organic molecule having a molecular weight of less than 5kD.

129. The cell according to claim 128, wherein at least one of the ligand-binding domains binds the ligand with a Kd less than or equal to 10^-6 M.